Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1710201 | 0.92 | ATM (0.40) | ATMPOLBHRH3 | |
| SCHEMBL2449137 | 0.85 | ATM (0.40) | ATMHRH3 | |
| SCHEMBL1265815 | 0.84 | CTSK (0.39) | ATMSIGMAR1ALDH1A1 | |
| SCHEMBL743576 | 0.84 | CTSK (0.39) | ATMSIGMAR1ALDH1A1 | |
| SCHEMBL1487188 | 0.84 | CTSK (0.39) | ATMSIGMAR1ALDH1A1 | |
| SCHEMBL10205020 | 0.83 | ATM (0.42) | ATMALDH1A1 | |
| SCHEMBL612827 | 0.81 | CA1 (0.42) | SIGMAR1ALDH1A1 | |
| SCHEMBL475538 | 0.81 | CA1 (0.42) | SIGMAR1ALDH1A1 | |
| SCHEMBL1061969 | 0.81 | CA1 (0.42) | SIGMAR1ALDH1A1 | |
| SCHEMBL30301525 | 0.81 | ATM (0.33) | ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250205259-A1 | CLASS OF 7-((FIVE-MEMBERED HETEROCYCLIC)METHYL)-8-CARBOXYLIC ACID-BENZO CYCLIC BORATE DERIVATIVES AND USES THEREOF | FUAN PHARMACEUTICAL GROUP CHONGQING SUNHORIZON PHARM-TECH CO., LTD (CN) | 2025-06-26 | — | — | US | disclosed |
| EP-4553079-A1 | CLASS OF 7-((FIVE-MEMBERED HETEROCYCLIC)METHYL)-8-CARBOXYLIC ACID-BENZO CYCLIC BORATE DERIVATIVES AND USES THEREOF | Fuan Pharmaceutical Group Chongqing Sunhorizon Pharm-Tech Co., Ltd (CN) | 2025-05-14 | — | — | EP | disclosed |
| CN-117980312-A | 7- ((Five membered heterocycle) methyl) -8-carboxylic acid-benzocyclobutane ester derivative and application thereof | 福安药业集团重庆三禾兴医药科技有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-113423711-B | Thieno [3,2-B ] pyridine derivatives as UDP glycosyltransferase inhibitors and methods of use thereof | 建新公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2024-03-14 | — | — | US | disclosed |
| US-11912682-B2 | Isoindolinone compounds | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117343088-A | 7- ((five membered heterocycle) methyl) -8-carboxylic acid-benzocyclobutane ester derivative and application thereof | 福安药业集团重庆三禾兴医药科技有限公司 | 2024-01-05 | — | — | CN | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| US-20230391779-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2023-12-07 | — | — | US | disclosed |
| CN-117157288-A | Pyridine derivative, preparation method and application thereof | 成都苑东生物制药股份有限公司 | 2023-12-01 | — | — | CN | disclosed |
| WO-2016091774-A1 | PIPERIDINE SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES WITH INHIBITORY ACTIVITY ON THE REPLICATION OF THE RESPIRATORY SYNCYTIAL VIRUS (RSV) | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-16 | — | — | WO | disclosed |
| EP-2101759-A1 | METHODS OF USING MEK INHIBITORS | Exelixis, Inc. (US) | 2009-09-23 | — | — | EP | disclosed |
| WO-2009080682-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2009-07-02 | — | — | WO | disclosed |
| EP-1686996-A4 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | NOVARTIS VACCINES & DIAGNOSTIC (US) | 2008-11-12 | — | — | EP | disclosed |
| WO-2008124085-A2 | METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS | EXELIXIS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008076415-A1 | METHODS OF USING MEK INHIBITORS | EXELIXIS, INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1686996-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2006-08-09 | — | — | EP | disclosed |
| EP-1651229-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | Chiron Corporation (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005051391-A1 | QUINAZOLINONE COMPOUNDS WITH REDUCED BIOACCUMULATION | CHIRON CORPORATION (US) | 2005-06-09 | — | — | WO | disclosed |
| WO-2004112793-A1 | GUANIDINO-SUBSTITUTED QUINAZOLINONE COMPOUNDS AS MC4-R AGONISTS | CHIRON CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230391779-A1 | BICYCLIC COMPOUNDS, COMPOSITIONS AND USE THEREOF | CYP11B2, CYP11B1, CYP27A1 | ATM 4007/4885POLB 1913/4885HRH3 3425/4885 |
| US-20240083869-A1 | ISOINDOLINONE COMPOUNDS | CYP4F2, AOC2, AOC3 | ATM 3418/4885POLB 3996/4885HRH3 652/4885 |
| US-20250205259-A1 | CLASS OF 7-((FIVE-MEMBERED HETEROCYCLIC)METHYL)-8-CARBOXYLIC ACID-BENZO CYCLIC BORATE DERIVATIVES AND USES THEREOF | BCAT2, BPGM, ME1 | ATM 546/4885POLB 2047/4885HRH3 3053/4885 |
| US-11912682-B2 | Isoindolinone compounds | CYP4F2, AOC2, AOC3 | ATM 3418/4885POLB 3996/4885HRH3 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.